Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.57 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.43 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15869655 | 1.00 | FOLH1 (0.57) | FOLH1ENPEPCPB2GSTK1TBXAS1 | |
| SCHEMBL15869595 | 1.00 | FOLH1 (0.57) | FOLH1ENPEPCPB2GSTK1TBXAS1 | |
| SCHEMBL1173389 | 1.00 | FOLH1 (0.57) | FOLH1ENPEPCPB2GSTK1TBXAS1 | |
| SCHEMBL15869592 | 1.00 | FOLH1 (0.57) | FOLH1ENPEPCPB2GSTK1TBXAS1 | |
| SCHEMBL4127084 | 1.00 | FOLH1 (0.57) | FOLH1ENPEPCPB2GSTK1TBXAS1 | |
| SCHEMBL15869568 | 1.00 | FOLH1 (0.57) | FOLH1ENPEPCPB2GSTK1TBXAS1 | |
| SCHEMBL9637766 | 0.86 | FOLH1 (0.50) | FOLH1ENPEPCPB2GSTK1GPR84 | |
| SCHEMBL9637650 | 0.86 | FOLH1 (0.50) | FOLH1ENPEPCPB2GSTK1GPR84 | |
| SCHEMBL9637745 | 0.86 | FOLH1 (0.50) | FOLH1ENPEPCPB2GSTK1GPR84 | |
| SCHEMBL9638476 | 0.86 | FOLH1 (0.50) | FOLH1ENPEPCPB2GSTK1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110605-B2 | Compound for inactivating viruses and bacteria and method of making same | NATIONAL TAIWAN UNIVERSITY (TW) | 2012-02-07 | — | — | US | claimed |
| US-20110015435-A1 | COMPOUND FOR INACTIVATING VIRUSES AND BACTERIA AND METHOD OF MAKING SAME | NATIONAL TAIWAN UNIVERSITY (TW) | 2011-01-20 | — | — | US | claimed |
| US-8776367-B2 | Method of manufacturing an electret film | NATIONAL TAIWAN UNIVERSITY (TW) | 2014-07-15 | — | — | US | disclosed |
| US-8110605-B2 | Compound for inactivating viruses and bacteria and method of making same | NATIONAL TAIWAN UNIVERSITY (TW) | 2012-02-07 | — | — | US | disclosed |
| US-8110605-B2 | Compound for inactivating viruses and bacteria and method of making same | NATIONAL TAIWAN UNIVERSITY (TW) | 2012-02-07 | — | — | US | disclosed |
| JP-2011020994-A | MEDICINE FOR BREAKING VIRUS AND BACTERIUM AND SUPPRESSING CONTAGION AND GROWTH OF THE SAME AND METHOD | NATIONAL TAIWAN UNIV | 2011-02-03 | — | — | JP | disclosed |
| US-20110015435-A1 | COMPOUND FOR INACTIVATING VIRUSES AND BACTERIA AND METHOD OF MAKING SAME | NATIONAL TAIWAN UNIVERSITY (TW) | 2011-01-20 | — | — | US | disclosed |
| US-20110015435-A1 | COMPOUND FOR INACTIVATING VIRUSES AND BACTERIA AND METHOD OF MAKING SAME | NATIONAL TAIWAN UNIVERSITY (TW) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015435-A1 | COMPOUND FOR INACTIVATING VIRUSES AND BACTERIA AND METHOD OF MAKING SAME | MGMT, CMBL, HAVCR2 | FOLH1 2553/4885ENPEP 807/4885CPB2 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.